Mild Cognitive Impairment
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Meets the diagnostic criteria for mild cognitive impairment (MCI) in Western medicine; (2) Male, aged 50-75 years; (3) Cognitive decline symptoms in MCI subjects have persisted for 3 months or longer; (4) Montreal Cognitive Assessment (MoCA) scores: =13 for illiterate individuals, =19 for those with primary education, and =24 for those with junior high school education or higher. Mini-Mental State Examination (MMSE) scores: >17 for illiterate individuals, >20 for those with primary education, and >24 for those with junior high school education or higher; (5) No treatment for mild cognitive impairment has been received in the past month, including Western medicine, traditional Chinese medicine (TCM) formulations, TCM decoctions, acupuncture, massage, cognitive-behavioral therapy, etc.; (6) No motor impairment in the upper limbs, no articulation disorders, voice disorders, or other organic speech disorders, and no uncorrected hearing impairments; (7) Proficient in Chinese, able to communicate normally, understand the content of the assessment scales, and cooperate with the treatment; (8) Voluntarily participates in this study and is willing to complete the investigation; (9) Agrees to and signs the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients who do not meet the diagnostic criteria for mild cognitive impairment in Western medicine; (2) Patients who have been clinically diagnosed with dementia (including Alzheimer's disease, vascular dementia, mixed dementia, etc.); (3) Patients with cognitive impairment caused by other diseases (e.g., Parkinson's disease, epilepsy, intracranial tumors, cranial trauma, etc.); (4) Patients with a history of stroke; (5) Patients with severe diseases, including endocrine system diseases, musculoskeletal diseases, autoimmune diseases, infectious diseases, diabetes, and other metabolic diseases; (6) Patients who need to take long-term medications that may lead to cognitive decline, such as antipsychotics, sedative-hypnotics, antihistamines, anticholinergics, theophylline, etc.; (7) Patients with a history of adult affective disorders or severe neurological deficits (e.g., various aphasia, agnosia), or currently diagnosed with schizoaffective disorder, schizophrenia, or primary adult affective disorders; (8) Patients with balance disorders or a history of severe diseases such as myasthenia gravis, knee replacement surgery, or severe lumbar disc herniation; (9) Patients currently participating in other professional cognitive intervention clinical trials that may affect the outcome evaluation of this study; (10) Patients who refuse to cooperate with this investigation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Lawton Cognitive Assessment Scale;Traditional Chinese Medicine constitution;Mini-Mental State Examination Scale;Activities of Daily Living Scale;Blood biomarker; | — |
Countries
China
Contacts
Shanghai University of Traditional Chinese Medicine